Pharmaceutical preparations containing umeclidinium bromide and vilanterol triphenylacetate

Through the drug preparation of Umebium bromide and Vilanterol dissolved in water, combined with soft mist or atomization inhalation technology, the problem of low drug deposition rate of dry powder inhaler is solved, and efficient drug lung partial distribution and long-term stability are achieved improves therapeutic effect and safety.

CN115768404BActive Publication Date: 2024-11-08GUANGZHOU ANOVENT PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202180038075.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-06-09
Filing Date
2021-06-09
Publication Date
2024-11-08
Estimated Expiration
2041-06-09

AI Technical Summary

Technical Problem

The existing dry powder inhalers have low pulmonary deposition rate of drugs during administration, resulting in increased side effects and uneven distribution of drugs in the lungs, making it difficult to achieve efficient therapeutic effects.

Method used

Using drug preparations of Umebromine and Vilanterol dissolved in water, administered through soft mist or atomized inhalation device, using propellant-free aerosol technology to improve the deposition rate of the drug in the lungs, and through ultrasound Or air pressure atomizer to achieve better particle size distribution and stability.

Benefits of technology

It significantly improves the deposition rate of the drug in the lungs, improves the therapeutic effect, reduces side effects, and the preparation has long-term stability during storage, meeting the storage requirements of at least one year.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115768404B_ABST
    Figure CN115768404B_ABST
Patent Text Reader

Abstract

The present invention relates to a liquid pharmaceutical preparation and a method for administering the pharmaceutical preparation by atomizing the pharmaceutical preparation in an inhaler. The pharmaceutical preparation without a propellant comprises: (a) an active substance selected from umeclidinium bromide and vilanterol triphenylacetate; (b) a solvent; (c) a pharmacologically acceptable solubilizer; (d) a pharmacologically acceptable preservative; (e) a pharmacologically acceptable stabilizer; and optionally other pharmaceutically acceptable additives.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Priority declaration

[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 036,478, filed on June 9, 2020, which is incorporated herein by reference in its entirety. Background of the Invention

[0004] Umeclidinium bromide, chemically known as 1-[2-(benzyloxy)ethyl]-4-(hydroxydiphenylmethyl)-1-azobicyclo[2.2.2]octane bromide, has the following chemical structure:

[0005]

[0006] Vilanterol triphenylacetate, chemically named triphenylacetate-4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol (1:1), has the following chemical structure:

[0007]

[0008] Umeclidinium is a long-acting muscarinic receptor antagonist (also known as an anticholinergic). It is a quinuclidine derivative that is active against multiple muscarinic receptor subtypes. Umeclidinium exerts its bronchodilator activity by competitively inhibiting the binding of acetylcholine to muscarinic receptors on airway smooth muscle. It exhibits slow reversibility at the human M3 muscarinic receptor subtype in vitro and a long duration of action in vivo when administered directly to the lungs in preclinical models.

[0009] Vilanterol is a selective, long-acting β2-adrenergic receptor agonist (β2-adrenergic agonist). The pharmacological effects of β2-adrenergic agonists, including vilanterol, are at least partially attributed to their stimulation of intracellular adenylate cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic 3',5'-monophosphate adenosine (cyclic AMP). Increased cyclic AMP levels lead to relaxation of bronchial smooth muscle and inhibit the release of mediators of immediate hypersensitivity reactions in cells, particularly mast cells.

[0010] Both compounds have valuable pharmacological properties. Umeclidinium and vilanterol may provide therapeutic benefit in the treatment of asthma or chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

[0011] However, umeclidinium and vilanterol are currently formulated as dry powders for inhalation in a light grey and red plastic inhaler containing 2 foil blister strips, one containing umeclidinium and the other containing vilanterol.

[0012] The present invention relates to a pharmaceutically acceptable salt of umeclidinium bromide and vilanterol dissolved in water and a propellant-free inhalable formulation containing inactive ingredients that can be administered using a soft mist or nebulizer inhalation device, and the propellant-free inhalable aerosol produced thereby. The pharmaceutical formulation is particularly suitable for administration using a soft mist inhalation or nebulizer device, which has better lung deposition (usually up to 55-60%, even up to 85-95%) compared to administration using a dry powder inhalation device.

[0013] The pharmaceutical preparations of the present invention are particularly suitable for administering the active substance by soft mist or nebulized inhalation for the treatment of asthma and chronic obstructive pulmonary disease. Summary of the invention

[0014] The present invention relates to a pharmaceutical preparation of umeclidinium bromide and vilanterol and a pharmaceutically acceptable salt or solvate thereof which can be administered by soft mist or atomized inhalation. The pharmaceutical preparation of the present invention meets high quality standards.

[0015] One aspect of the present invention provides an aqueous pharmaceutical formulation comprising umeclidinium bromide and vilanterol, which meets the high standards required for optimal aerosolization of the formulation using the inhaler mentioned above. It meets the high standards required for optimal aerosolization of the formulation using the inhaler mentioned above. The stability of the active substance in the formulation should be a storage time of several years, preferably at least one year, more preferably at least three years.

[0016] Another aspect is to provide a propellant-free formulation comprising a solution of umeclidinium and vilanterol or a pharmaceutically acceptable salt or solvate thereof, which is aerosolized under pressure using an inhaler device, preferably a soft mist or nebulizer inhaler device, and the aerosol produced by the final aerosolization can be repeatedly within a specified particle size range. In one embodiment, the particle size is less than about 10 μm.

[0017] Another aspect of the present invention is to provide a pharmaceutical formulation comprising a nebulized solution of umeclidinium and vilanterol and an inactive excipient, which can be administered by aerosolizing the solution using an ultrasound-based or air pressure-based nebulizer / inhaler. The pharmaceutical stability of the formulation is a shelf life of at least several months. In one embodiment, the shelf life is at least 1 month. In one embodiment, the shelf life is at least 6 months. In one embodiment, the shelf life is at least one year. In one embodiment, the shelf life is at least three years.

[0018] More specifically, another aspect is to provide a stable pharmaceutical formulation comprising an aqueous solution of umeclidinium bromide and vilanterol and other excipients, which can be administered by soft mist inhalation using a nebulizer inhaler. The formulation of the present invention has substantially long-term stability. In one embodiment, the storage temperature of the formulation is about 1°C to about 30°C. In one embodiment, the storage temperature of the formulation is about 15°C to about 30°C. In one embodiment, the storage temperature of the formulation is below about 15°C. In one embodiment, the storage temperature of the formulation is about 2°C to about 8°C.

[0019] More specifically, another aspect of the present invention is to provide a stable pharmaceutical formulation comprising umeclidinium bromide and vilanterol and other excipients, which can be administered by atomizing the formulation using ultrasound, jet or mesh nebulizer. The formulation of the present invention has substantially long-term stability. In one embodiment, the storage temperature of the formulation is about 1°C to about 30°C. In one embodiment, the storage temperature of the formulation is about 15°C to about 30°C. In one embodiment, the storage temperature of the formulation is less than about 15°C. In one embodiment, the storage temperature of the formulation is about 2°C to about 8°C. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 A cross-section of the atomizer is shown in a stressed state.

[0021] Figure 2 The counter element of the atomizer is shown.

[0022] Figure 3 The aerodynamic particle size distribution of umeclidinium bromide and vilanterol triphenylacetate as described in Example 4 is shown.

[0023] Figure 4 The aerodynamic particle size distribution of umeclidinium bromide and vilanterol triphenylacetate as described in Example 7 is shown.

[0024] Figure 5 The impurity levels in samples 1-3 as described in Example 11 are shown. DETAILED DESCRIPTION

[0025] It is advantageous to administer liquid formulations of active substances without propellant gas using a suitable inhaler to achieve better distribution of the active substance in the lungs. More importantly, the lung deposition of drugs delivered by inhalation can be maximized.

[0026] Conventional pMDIs (pressurized metered dose inhalers) or DPIs (dry powder inhalers) deliver only about 20-30% of the drug to the lungs, resulting in a large amount of drug being deposited in the mouth and throat, which can then enter the stomach and cause unwanted side effects and / or secondary absorption through the oral digestive system.

[0027] Therefore, it is necessary to improve the delivery of inhaled drugs by increasing lung deposition. The soft mist or inhalation device disclosed in US20190030268 can significantly increase the lung deposition of inhalable drugs.

[0028] Such inhalers can nebulize small amounts of liquid formulations into aerosols suitable for therapeutic inhalation within a few seconds. Such inhalers are particularly suitable for the liquid formulations of the present invention.

[0029] A soft mist or atomizing device suitable for administering the aqueous pharmaceutical formulation of the present invention can atomize less than about 70 microliters, such as less than about 30 microliters, more specifically less than about 15 microliters of the pharmaceutical solution in one spray, so that the inhalable portion of the aerosol corresponds to a therapeutically effective amount. The average particle size of the aerosol formed by one spray is less than 15 microns, or less than 10 microns.

[0030] In one embodiment, the atomizing device for administering the pharmaceutical preparation of the present invention is a device in which less than 8 milliliters of drug solution can be atomized in one spray, so that the inhalable portion of the aerosol corresponds to the therapeutically effective amount. In one embodiment, an amount less than about 2 milliliters can be atomized in one spray, so that the inhalable portion of the aerosol corresponds to the therapeutically effective amount. In one embodiment, an amount less than about 1 milliliter can be atomized in one spray, so that the inhalable portion of the aerosol corresponds to the therapeutically effective amount. In one embodiment, the average particle size of the aerosol formed by one spray is less than about 15 microns. In one embodiment, the average particle size of the aerosol formed by one spray is less than about 10 microns.

[0031] Such devices for metered administration of propellant-free liquid pharmaceutical inhalable formulations have been described in detail, for example in US20190030268.

[0032] The drug solution in the nebulizer is converted into an aerosol that acts on the lungs. The drug solution is sprayed out by the nebulizer under high pressure.

[0033] In some inhalers that can be used with the present invention, the drug solution is stored in a container. In one example, the drug solution formulation of the present invention does not contain any components that may interact with the inhaler and affect the quality of the formulation drug or the aerosol produced. In one example, the drug formulation of the present invention is very stable when stored and can be used directly.

[0034] The formulation of the present invention used with the above-mentioned inhaler may contain additives, such as the disodium salt of edetic acid (sodium edetate), to reduce the incidence of nebulization abnormalities and stabilize the formulation. The formulation preferably has a minimum concentration of sodium edetate.

[0035] One aspect of the present invention is to provide a pharmaceutical formulation comprising umeclidinium bromide and vilanterol and other excipients that meets the high standards required for optimal aerosolization using a soft mist inhaler. In one embodiment, the formulation has a shelf life of at least several months or years. In one embodiment, the formulation has a shelf life of at least about 1 month. In one embodiment, the formulation has a shelf life of at least about 6 months. In one embodiment, the formulation has a shelf life of at least about one year. In one embodiment, the formulation has a shelf life of at least about three years.

[0036] Another aspect of the present invention is to provide a propellant-free formulation comprising a solution of umeclidinium bromide and vilanterol that can be aerosolized under pressure using an inhaler. In one embodiment, the inhaler is a soft mist inhaler or a nebulizer inhaler. In one embodiment, the aerosol produced by the inhaler reproducibly falls within a specified particle size range. In one embodiment, the particle size is less than about 10 μm.

[0037] Another aspect provides an aqueous pharmaceutical formulation as a solution containing umeclidinium bromide and vilanterol, and other inactive excipients that can be administered by inhalation.

[0038] "Umeclidinium or its salt or solvate" herein refers to any pharmaceutically acceptable counterion and its pharmaceutically acceptable solvate. "Vilanterol or its salt or solvate" herein refers to any pharmaceutically acceptable salt or solvate of Vilanterol. As used herein, the terms umeclidinium and Vilanterol refer to umeclidinium or its salt or solvate and Vilanterol or its salt or solvate, respectively.

[0039] In one embodiment, the pharmaceutical formulation comprises umeclidinium bromide.In one embodiment, the pharmaceutical formulation comprises vilanterol triphenylacetate.

[0040] In one embodiment, the active substance is a combination of umeclidinium bromide and vilanterol triphenylacetate.

[0041] In one embodiment, umeclidinium and vilanterol are dissolved in a solvent. In one embodiment, umeclidinium and vilanterol are dissolved in water. In one embodiment, umeclidinium and vilanterol triphenylacetate are dissolved in a solvent. In one embodiment, umeclidinium and vilanterol triphenylacetate are dissolved in water.

[0042] The concentration of umeclidinium and vilanterol in the final pharmaceutical preparation depends on the desired therapeutic effect. In one embodiment, the concentration range of umeclidinium in the preparation is about 2mg / 100ml to about 1050mg / 100ml. In one embodiment, the concentration range of umeclidinium in the preparation is about 10mg / 100ml to about 600mg / 100ml. In one embodiment, the concentration range of umeclidinium in the preparation is about 20mg / 100ml to about 350mg / 100ml. In one embodiment, the concentration range of vilanterol in the preparation is about 1mg / 100ml to about 550mg / 100ml. In one embodiment, the concentration range of vilanterol in the preparation is about 5mg / 100ml to about 300mg / 100ml. In one embodiment, in one embodiment, the concentration range of vilanterol in the preparation is about 10mg / 100ml to about 200mg / 100ml.

[0043] In one embodiment, the therapeutically effective dose of umeclidinium ranges from about 1 pg to about 130 pg. In one embodiment, the therapeutically effective dose of umeclidinium ranges from about 5 pg to about 120 pg. In one embodiment, the daily dose of umeclidinium ranges from about 16 pg to about 112 micrograms. In one embodiment, the therapeutically effective dose of umeclidinium ranges from about 30 pg to about 80 pg. In one embodiment, the therapeutically effective dose of umeclidinium ranges from about 40 pg to about 60 pg. In one embodiment, the therapeutically effective dose of umeclidinium ranges from about 56 pg. In one embodiment, the therapeutically effective dose of vilanterol triphenylacetate ranges from about 1 pg to about 100 pg. In one embodiment, the therapeutically effective dose of vilanterol triphenylacetate ranges from about 5 pg to about 80 pg. In one embodiment, the therapeutically effective dose of vilanterol triphenylacetate ranges from about 9 pg to about 60 pg. In one embodiment, the therapeutically effective dose of vilanterol triphenylacetate ranges from about 20 pg to about 40 pg. In one embodiment, the therapeutically effective dose of vilanterol triphenylacetate is about 30 pg. In one embodiment, the daily dose of umeclidinium is about 55.7 micrograms, while the daily dose of vilanterol triphenylacetate is about 30 micrograms. In one embodiment, the therapeutically effective dose of vilanterol triphenylacetate is about 30 pg. In one embodiment, the daily dose of umeclidinium is about 55.7 micrograms, while the daily dose of vilanterol triphenylacetate is about 30 micrograms. In one embodiment, the therapeutically effective dose of vilanterol triphenylacetate is about 30 pg. In one embodiment, the daily dose of umeclidinium is about 55.7 micrograms, while the daily dose of vilanterol triphenylacetate is about 30 micrograms.

[0044] In one embodiment, a soft mist device for administering the pharmaceutical formulation of the present invention can aerosolize about 10 to about 15 microliters, which can be used 1 to 4 times each time, so that the inhalable portion of the aerosol corresponds to a therapeutically effective amount.

[0045] In one embodiment, the formulation includes an acid or a base as a pH adjuster. In one embodiment, the pH adjuster is selected from hydrochloric acid, citric acid or a buffer thereof and / or a salt thereof.

[0046] Other pH adjusting agents may be used in the present invention. In one embodiment, the pH adjusting agent is sodium hydroxide.

[0047] Select suitable formulation pH to ensure stability. In one embodiment, the pH range is from about 2.0 to about 6.0. In one embodiment, the pH range is from about 3.0 to about 5.0. In one embodiment, the pH range is from about 4.0 to about 5.0.

[0048] In one embodiment, the formulation includes edetic acid (EDTA) or a known salt, edetic acid disodium or edetic acid disodium dihydrate as a stabilizer or complexing agent. In one embodiment, the formulation contains edetic acid and / or its salt.

[0049] Other similar stabilizers or complexing agents can be used in the formulations of the present invention.Examples of other stabilizers or complexing agents include, but are not limited to, citric acid, disodium edetate, and disodium edetate dihydrate.

[0050] As used herein, the phrase "complexing agent" refers to a molecule that is capable of entering into a complex bond. Preferably, these compounds should have the effect of complexing cations. In one embodiment, the concentration range of the stabilizer or complexing agent is about 1 mg / 100 ml to about 500 mg / 100 ml. In one embodiment, the concentration range of the stabilizer or complexing agent is about 5 mg / 100 ml to about 200 mg / 100 ml. In one embodiment, the stabilizer or complexing agent is disodium edetate dihydrate at a concentration of about 10 mg / 100 ml.

[0051] In one embodiment, all ingredients of the formulation are present in solution.

[0052] As used herein, the term "additive" refers to any pharmacologically acceptable and therapeutically useful substance that is not an active substance but can be formulated with the active substance in a pharmacologically suitable solvent to improve the quality of the pharmaceutical active substance formulation. Preferably, these additives have no significant pharmacological effect or at least no undesirable pharmacological effect in the context of the desired treatment.

[0053] Suitable additives include, but are not limited to, other stabilizers, complexing agents, antioxidants, surfactants and / or preservatives to extend the shelf life of the finished pharmaceutical formulation, vitamins and / or other additives known in the art.

[0054] Preservatives protect the formulation from contamination by pathogenic bacteria. Suitable preservatives include, but are not limited to, benzalkonium chloride, benzoic acid, and sodium benzoate. In one embodiment, the formulation contains benzalkonium chloride as the sole preservative. In one embodiment, the amount of preservative is from about 2 mg / 100 ml to about 300 mg / 100 ml. In one embodiment, the preservative is benzalkonium chloride in an amount of about 10 mg / 100 ml.

[0055] In one embodiment, the formulation includes a solubilizer, such as Tween 80 or a cyclodextrin derivative. In one embodiment, the solubilizer is a cyclodextrin derivative or a salt thereof. The solubilizer increases the solubility of the active ingredient or other excipients. In one embodiment, the solubilizer is sulfobutyl ether β-cyclodextrin or a salt thereof.

[0056] In one embodiment of the soft mist inhalation formulation, the formulation includes a surfactant or other solubilizer, such as Tween 80 (polysorbate 80) or a cyclodextrin derivative. In one embodiment, the surfactant or other solubilizer is present in an amount ranging from about 1g / 100ml to about 40g / 100ml. In one embodiment, the surfactant or other solubilizer is present in an amount ranging from about 10g / 100ml to about 30g / 100ml. In one embodiment, the surfactant or other solubilizer is present in an amount ranging from about 15g / 100ml to about 25g / 100ml. In one embodiment, the surfactant or other solubilizer is a cyclodextrin derivative or a salt thereof. In one embodiment, the surfactant or other solubilizer is sulfobutyl ether β-cyclodextrin. In one embodiment, sulfobutyl ether β-cyclodextrin is present in an amount ranging from about 1g / 100ml to about 40g / 100ml. In one embodiment, sulfobutyl ether β-cyclodextrin is present in an amount ranging from about 10g / 100ml to about 30g / 100ml. In one embodiment, sulfobutyl ether beta-cyclodextrin is present in an amount ranging from about 15 g / 100 ml to about -25 g / 100 ml.

[0057] Another aspect of the present invention is to provide a stable pharmaceutical soft mist formulation comprising umeclidinium bromide and vilanterol and other excipients, which can be administered by soft mist inhalation using a nebulizer inhaler. In one embodiment, the storage temperature of the formulation is about 1°C to about 30°C. In one embodiment, the storage temperature of the formulation is about 15°C to about 30°C. In one embodiment, the storage temperature of the formulation is below about 15°C. In one embodiment, the storage temperature of the formulation is about 2°C to about 8°C.

[0058] Another aspect of the present invention is to provide a pharmaceutical formulation comprising a nebulized solution of umeclidinium bromide and vilanterol and other inactive excipients, which can be administered by nebulization inhalation using an ultrasound-based or air pressure-based nebulizer / inhaler. In one embodiment, the storage temperature of the formulation is about 1°C to about 30°C. In one embodiment, the storage temperature of the formulation is about 15°C to about 30°C. In one embodiment, the storage temperature of the formulation is below about 15°C. In one embodiment, the storage temperature of the formulation is about 2°C to about 8°C.

[0059] Another aspect of the present invention is to provide a stable pharmaceutical formulation comprising umeclidinium bromide and vilanterol and other excipients, which can be administered by aerosol inhalation using an ultrasound-based or air pressure-based nebulizer / inhaler. The formulation has substantially long-term stability. In one embodiment, the storage temperature of the formulation is about 1°C to about 30°C. In one embodiment, the storage temperature of the formulation is about 15°C to about 30°C. In one embodiment, the storage temperature of the formulation is less than about 15°C. In one embodiment, the storage temperature of the formulation is about 2°C to about 8°C.

[0060] In one embodiment, the formulation includes sodium chloride. In one example, the concentration of sodium chloride ranges from about 0.1 g / 100 ml to about 0.9 g / 100 ml.

[0061] In one embodiment, the concentration range of umeclidinium in the aerosol formulation is from about 7mcg / 2ml to about 3700mcg / 2ml. In one embodiment, the concentration range of umeclidinium in the aerosol formulation is from about 35mcg / 2ml to about 1800mcg / 2ml. In one embodiment, the concentration range of umeclidinium in the aerosol formulation is from about 50mcg / 2ml to about 100mcg / 2ml. In one embodiment, the concentration range of vilanterol in the aerosol formulation is from about 4mcg / 2ml to about 2000mcg / 2ml. In one embodiment, the concentration range of vilanterol in the aerosol formulation is from about 20mcg / 2ml to about 1000mcg / 2ml. In one embodiment, the concentration range of vilanterol in the aerosol formulation is from about 30mcg / 2ml to about 50mcg / 2ml.

[0062] In one embodiment, the formulation for aerosolization includes a surfactant or other solubilizing agent, such as Tween 80 or a cyclodextrin derivative. In one embodiment, the surfactant or other solubilizing agent is a cyclodextrin derivative or a salt thereof. In one embodiment, the surfactant or other solubilizing agent is sulfobutyl ether b-cyclodextrin.

[0063] It has been found that sulfobutyl ether beta-cyclodextrin not only improves the solubility but also advantageously improves the stability of the active ingredient.

[0064] Another aspect of the present invention is to provide a stable pharmaceutical formulation for atomization, which contains umeclidinium bromide and vilanterol and other excipients, which can be administered by soft mist inhalation using a nebulizer or by using ultrasound-based or air pressure-based atomization inhalation. The preparation has essentially long-term stability. In one embodiment, the preparation has a storage time of at least about 6 months at a temperature of about 15°C to about 25°C. In one embodiment, the preparation has a storage time of at least about 12 months at a temperature of about 15°C to about 25°C. In one embodiment, the preparation has a storage time of at least about 24 months at a temperature of about 15°C to about 25°C. In one embodiment, the preparation has a storage time of at least about 36 months at a temperature of about 15°C to about 25°C.

[0065] The pH of the formulation affects the stability and solubility of umeclidinium and vilanterol in the formulation. The pH can be adjusted to the desired value by adding an acid (e.g., HCl) or by adding a base (e.g., NaOH).

[0066] In one embodiment, the pH of the aerosolized formulation ranges from about 3 to about 6. In one embodiment, the pH of the aerosolized formulation ranges from about 3 to about 5. In one embodiment, the pH of the aerosolized formulation ranges from about 4 to about 5.

[0067] The aerosol formulation of the present invention can be filled into a tank to provide a highly stable formulation for an aerosol device. The formulation is substantially free of particle growth, morphological changes or precipitation. There is also no or substantially no problem of suspended particles depositing on the surface of the tank or valve, so the formulation can be uniformly discharged from a suitable aerosol device at a high dose. Suitable aerosolizers include, but are not limited to, ultrasonic aerosolizers; jet aerosolizers; mesh aerosolizers, such as the Pari eFlow aerosol inhaler; or other commercially available ultrasonic aerosolizers, jet aerosolizers or mesh aerosolizers.

[0068] In one embodiment, the inhalation device is a soft mist inhaler. For the production of an aerosol, preferably an inhaler of the type described herein is used to administer a pharmaceutical soft mist formulation containing umeclidinium bromide and vilanterol. Here, we again explicitly refer to the patent documents mentioned above, to which reference is made, which are incorporated herein by reference.

[0069] This soft mist inhaler device for propellant-free administration of metered amounts of liquid drug preparations for inhalation is described in detail in US20190030268 entitled "Inhalation nebulizer with locking function and counter".

[0070] The drug formulation is converted into an aerosol for the lungs by a nebulizer, which uses high pressure to spray the formulation.

[0071] The inhalation device can be carried anywhere by the patient, has a cylindrical shape and a convenient size of less than about 8 cm to about 18 cm long and about 2.5 cm to about 5 cm wide. The nebulizer sprays a certain volume of the drug formulation through a small nozzle under high pressure to produce an inhalable aerosol.

[0072] The inhalation device can be carried anywhere by the patient, has a cylindrical shape and a convenient size of less than about 8 cm to about 18 cm long and about 2.5 cm to about 5 cm wide. The nebulizer sprays a certain volume of the drug formulation through a small nozzle under high pressure to produce an inhalable aerosol.

[0073] The sprayer 1 has the above-mentioned blocking function and counter for spraying the drug liquid 2 (such as the drug preparation of the present invention), and its pressure-bearing state is as follows: Figure 1 The above-mentioned sprayer 1 is a portable inhaler without propellant.

[0074] Figure 1 A cross section of the atomizer is shown, including the blocking function and the counter under pressure.

[0075] For the above typical nebulizer 1, an aerosol 14 that can be inhaled by a patient is generated by atomization of the liquid 2. In one example, the aerosol 14 is the pharmaceutical preparation of the present invention. According to the severity of the patient's illness, the pharmaceutical preparation is administered at least once a day, more specifically, multiple times a day, preferably at predetermined time intervals.

[0076] In one example, the above-mentioned nebulizer 1 has a replaceable and insertable container 3, which contains a medicinal liquid 2. Therefore, a container for containing the liquid 2 is formed in the container 3. In particular, the liquid 2 is located in a liquid compartment 4 formed by a foldable bag in the container 3.

[0077] In one example, the amount of liquid 2 used for inhalation nebulizer 1 can provide a sufficient amount for the patient, for example, up to about 200 doses. In one example, the volume of container 3 is about 2 ml to about 10 ml. The pressure generator 5 in the nebulizer 1 is used to deliver and atomize the liquid 2, especially in a predetermined dose. The liquid 2 is released and sprayed in a single dose, for example, about 5 to about 30 microliters for spraying.

[0078] In one example, the sprayer 1 may have a pressure generator 5 and a bracket 6, a drive spring 7, a delivery tube 9, a check valve 10, a pressure chamber 11, and a nozzle 12 in a mouthpiece 13. The container 3 is locked in the sprayer 1 by the bracket 6, so that the delivery tube 9 is inserted into the container 3. The container 3 can be separated from the sprayer 1 for replacement.

[0079] In one example, when the driving spring 7 is forced in the axial direction, the delivery pipe 9 and the container 3 and the bracket 6 will move downward. Then, the liquid 2 will be sucked into the pressure chamber 11 through the delivery pipe 9 and the check valve 10.

[0080] In one example, after the support 6 is released, the stress is relieved. In this process, the delivery tube 9 and the closed check valve 10 are moved upward back to their original positions by releasing the drive spring 7. This causes the liquid 2 to be pressurized in the pressure chamber 11. The liquid 2 is then pushed through the nozzle 12 and atomized into an aerosol 14 under pressure. When air is inhaled into the mouthpiece 13 through the air inlet 15, the patient can inhale the aerosol 14 through the mouthpiece 13.

[0081] In one example, the above-mentioned nebulizer 1 has an upper housing 16 and an inner part 17, which is rotatable relative to the upper housing 16. The lower housing 18 is manually operable to be attached to the inner part 17. The lower housing 18 can be separated from the nebulizer 1 so that the container 3 can be replaced and inserted.

[0082] In one example, the above-mentioned sprayer 1 may have a lower housing 18, which carries the internal component 17 and is rotatable relative to the upper housing 16. As a result of the rotation and engagement between the upper component 17 and the bracket 6, the bracket 6 moves axially to the counter under the force of the drive spring 7, which is compressed through the gear 20.

[0083] In the embodiment in the pressurized state, the container 3 moves downward and reaches the final position, such as Figure 1 As shown. The drive spring 7 is compressed in this final position. The bracket 6 is then fastened. The container 3 and the delivery tube 9 are prevented from moving upward, thereby preventing the drive spring 7 from loosening.

[0084] In one example, the atomization process occurs after the bracket 6 is released. The container 3, the delivery tube 9 and the bracket 6 are moved back to the starting position by the driving spring 7. This movement is called a large shift. When a large shift occurs, the check valve 10 is closed, and the liquid 2 is subjected to pressure in the pressure chamber 11 through the delivery tube 9, and then the liquid 2 is pushed out under pressure and atomized.

[0085] In one example, the above-mentioned sprayer 1 can have a clamping function. During clamping, the container 3 is used to perform extrusion or withdrawal of the liquid 2 during the atomization process. The gear 20 has a curved surface 21 on the upper housing 16 and / or the bracket 6, and when the bracket 6 rotates relative to the upper housing 16, the curved surface 21 can make the bracket 6 move axially.

[0086] In one example, the support 6 is not blocked for too long and a large shift can be performed. The liquid 2 is sprayed and atomized.

[0087] In one example, when the bracket 6 is in the clamped position, the curved surface 21 is disengaged. The gear 20 then releases the bracket 6 for reverse axial movement.

[0088] In one embodiment, the sprayer 1 comprises Figure 2 The counter shown in FIG. The counter has a worm 24 and a counting ring 26. In one example, the counting ring 26 is annular and has a toothed portion at the bottom. The worm 24 has an upper end gear and a lower end gear. The upper end gear is in contact with the upper housing 16. The upper housing 16 has an internal protrusion 25. When the sprayer 1 is used, the upper housing 16 rotates; when the protrusion 25 passes the upper end gear of the worm 24, the worm 24 is driven to rotate. The rotation of the worm 24 drives the counter 26 to rotate through the lower end gear. This produces a counting effect.

[0089] In one embodiment, the locking mechanism is mainly implemented by two protrusions. Protrusion A is located on the outer wall of the lower unit of the internal component. Protrusion B is located on the inner wall of the counter. The lower unit of the internal component is nested in the counter. The counter can rotate relative to the lower unit of the internal component. Due to the rotation of the counter, the number displayed on the counter can change as the number of actuations increases, which can be observed by the patient. After each actuation, the number displayed on the counter will change. Once the predetermined number of actuations is reached, protrusions A and protrusions B will contact each other and the counter will not be able to rotate further. This will block the nebulizer and prevent it from being used further. The number of actuations of the device can be counted by the counter.

[0090] Nebulizing devices include, but are not limited to, soft mist inhalers, ultrasonic nebulizers, air compression nebulizers, and mesh-based nebulizers.

[0091] The soft mist inhaler provides pressure to spray a metered dose of drug solution, forming two high-speed jets that collide with each other to form droplets with smaller particles.

[0092] The ultrasonic atomizer amplifies the oscillation signal of the main circuit board through a high-power triode and transmits it to the ultrasonic chip. The ultrasonic chip converts electrical energy into ultrasonic energy. Ultrasonic energy can atomize water-soluble drugs into tiny mist particles of about 1pm to about 5pm at room temperature. With the help of the internal fan, the drug particles are ejected.

[0093] The air compression nebulizer is mainly composed of a compressed air source and a nebulizer. After the compressed gas passes through a narrow opening at high speed, it is suddenly decompressed, generating negative pressure locally, and sucking the active substance solution out of the container through siphon action. When subjected to the high-speed airflow, the active substance solution is broken into small aerosol particles through collision.

[0094] The mesh-based nebulizer contains a stainless steel mesh covered with micropores of about 3 pm in diameter. The number of micropores exceeds 1,000. The mesh is conical in shape, with the bottom of the cone facing the liquid surface. Under pressure, the mesh vibrates at a frequency of about 130 KHz. The high vibration frequency breaks the surface tension of the drug solution in contact with the mesh, producing a low-speed aerosol. Specific embodiments

[0096] Materials and Reagents:

[0097] 50% benzalkonium chloride aqueous solution, purchased from Merck.

[0098] Disodium EDTA dihydrate was purchased from Merck.

[0099] Sodium hydroxide was purchased from Titan Reagent.

[0100] Hydrochloric acid was purchased from Titan Reagents, and sodium chloride was purchased from Merck.

[0101] Sulfonbutyl ether b-cyclodextrin was purchased from China Zhiyuan Biotechnology Co., Ltd. Umeclidinium bromide was purchased from Anhui Dexinjia Pharmaceutical Co., Ltd.

[0102] Vilanterol was purchased from Sidley Pharmaceuticals Co., Ltd.

[0103] Example 1

[0104] The soft mist inhalation solution (Sample I) was prepared as follows:

[0105] 50% benzalkonium chloride aqueous solution, edetate disodium dihydrate, SBECD were dissolved in 90 ml of purified water according to the amounts in Table 1. Umeclidinium bromide and vilanterol triphenylacetate were added to the solution and the resulting mixture was sonicated until the components were completely dissolved. The solution was adjusted to the target pH value with hydrochloric acid or sodium hydroxide. Finally, purified water was added to a final volume of 100 ml.

[0106] Table 1: Composition of Sample I

[0107] Element Sample I Umeclidinium 37.1mg Vilanterol triphenylacetate 20mg SBECD 5g 50% Benzalkonium Chloride Aqueous Solution 20mg Edetate disodium dihydrate 10mg hydrochloric acid To pH 4.0 Purified water Add to 100ml

[0108] Example 2

[0109] The thermal stability of Sample I of Example 1 at 60°C is provided below.

[0110] Table 2: Thermal stability of sample I of Example 1 at 60°C

[0111]

[0112]

[0113] As shown in Table 2, UB and VT were very stable due to the addition of sulfobutyl ether b-cyclodextrin.

[0114] Example 3

[0115] The soft mist inhalation solution (Sample II) was prepared as follows:

[0116] Dissolve 50% benzalkonium chloride aqueous solution, edetate disodium dihydrate, and SBECD in 90 ml of purified water according to Table 3. Add umeclidinium bromide and vilanterol triphenylacetate and sonicate the resulting mixture until the components are completely dissolved. Adjust the solution to the target pH value with hydrochloric acid or sodium hydroxide. Finally, add purified water to a final volume of 100 ml.

[0117] Table 3: Composition of Sample II

[0118] Element Sample II Umeclidinium 21mg Vilanterol triphenylacetate 11mg SBECD 5g 50% Benzalkonium Chloride Aqueous Solution 20mg Edetate disodium dihydrate 10mg hydrochloric acid To pH 4.0 Purified water Add to 100ml

[0119] Example 4

[0120] Aerodynamic particle size distribution of soft mist inhalation solution (Sample II of Example 3):

[0121] Sample II was sprayed using a soft mist inhaler, and the aerodynamic size distribution of the sample II droplets was measured using a next generation impactor (NGI). The Next Generation Impactor was operated at a flow rate of 30 L / min to determine the particle size distribution. For each impactor experiment, the impactor collection table was coated with silicone oil. The particle size distribution is expressed as mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD). The results showed that the MMAD of vilanterol triphenylacetate and umeclidinium bromide was less than 10 pm, while the GSD of vilanterol triphenylacetate and umeclidinium bromide was less than 5% (Table 4).

[0122] Table 4: Aerodynamic particle size distribution

[0123] Particle size parameters Vilanterol triphenylacetate Umeclidinium MMAD(μm) 3.92 3.92 GSD(%) 2.32 2.32

[0124] Example 5

[0125] Sample II of Example 3 was sprayed using a soft mist inhalation device. Malvern Spraytec (STP5313) was used to measure the droplet size. The results are shown in Table 5.

[0126] Table 5: Droplet size distribution of Example 3 Sample II sprayed using a soft mist inhaler

[0127]

[0128]

[0129] Example 6

[0130] The nebulized inhalation solution (Sample III) was prepared as follows:

[0131] Sodium chloride and SBECD were dissolved in 90 ml of purified water according to Table 6. Umeclidinium bromide and vilanterol triphenylacetate were added, and the resulting mixture was sonicated until the components were completely dissolved. The solution was adjusted to the target pH value with hydrochloric acid or sodium hydroxide. Finally, purified water was added to a final volume of 100 ml.

[0132] Table 6: Composition of Sample III

[0133] Element Sample III Umeclidinium 7.4mg Vilanterol triphenylacetate 4.0mg SBECD 5g Sodium chloride 600mg Hydrochloric acid or sodium hydroxide To pH 4.0 Purified water Add to 100ml

[0134] Example 7

[0135] Aerodynamic particle size distribution of the nebulized inhalation solution (Sample III of Example 6):

[0136] Sample III was sprayed using a soft mist inhaler. The aerodynamic size distribution of the sample III droplets was measured using a next generation impactor (NGI). The Next Generation Impactor was operated at a flow rate of 15 L / min to determine the particle size distribution. For each impactor experiment, the impactor collection table was coated with silicone oil. The particle size distribution is expressed as mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD). The results showed that the MMAD of vilanterol triphenylacetate and umeclidinium bromide was less than 10 pm, while the GSD of vilanterol triphenylacetate and umeclidinium bromide was less than 5% (Table 7).

[0137] Table 7: Aerodynamic particle size distribution of the nebulized inhalation solution of Sample III of Example 6

[0138] Particle size parameters Vilanterol triphenylacetate Umeclidinium MMAD(μm) 3.48 3.48 GSD(%) 1.55 1.55

[0139] Example 8

[0140] Sample IV was prepared as follows:

[0141] Tween 80 was dissolved in 90 ml of purified water according to the amount in Table 8. Umeclidinium bromide and vilanterol triphenylacetate were added to the solution and the resulting mixture was sonicated until the components were completely dissolved. Purified water was finally added to a final volume of 100 ml.

[0142] Table 8: Composition of Sample IV

[0143]

[0144]

[0145] Example 9

[0146] Solubility in different co-solvents:

[0147] 5% Tween 80: Dissolve 5 g of Tween 80 in 100 g of purified water.

[0148] 5% sulfobutyl ether beta-cyclodextrin: Dissolve 5 g sulfobutyl ether beta-cyclodextrin in 100 g purified water.

[0149] 20% sulfobutyl ether beta-cyclodextrin: Dissolve 20 g sulfobutyl ether beta-cyclodextrin in 100 g purified water.

[0150] Table 9: Solubility of UB and VT in various solvents

[0151] Solvents UB solubility (μg / ml) VT solubility (μg / ml) Purified water 617.87 53.66 0.2mg / ml Tween 80 581.67 62.57 5% Tween 80 3540.95 1370.79 5% sulfobutyl ether β-cyclodextrin 3555.20 369.66 20% sulfobutyl ether β-cyclodextrin 3447.58 1399.30

[0152] As shown in Table 9, UB and VT were almost insoluble in purified water. When tween-80 and sulfobutyl ether β-cyclodextrin were both added at 5%, VT was found to be more soluble.

[0153] Example 10

[0154] The formulation and preparation of the nebulized inhalation solution (Samples 1-3) are as follows:

[0155] Table 10: Composition of Samples 1-3

[0156]

[0157] Sample preparation method:

[0158] SBECD or Tween 80 was dissolved in 90 ml of purified water according to the amounts provided in Table 10. UB and VT were added to the solution and the resulting mixture was sonicated until the components were completely dissolved. Purified water was finally added to a final volume of 100 ml.

[0159] Impurity detection method:

[0160] Instrument: HPLC waters J (2695 / 2996)

[0161] Column: ACE Excel 3C18-FPF V20-3880 150*4.6mm 3um

[0162] Wavelength: 200 nm

[0163] Flow rate: 0.8 ml / min

[0164] Column temperature: 40°C

[0165] Time: 96 minutes Mobile phase A: Dissolve 2.87 g sodium heptane sulfonate and 2.5 g sodium dihydrogen phosphate in 1 L of water and adjust the pH to 4.0 with phosphoric acid. Mobile phase B: Acetonitrile.

[0166] Gradient elution curve:

[0167] Time (min) Mobile phase A (%) Mobile phase B (%) 0 85 15 1 85 15 10 65 35 15 65 35 60 48 52 75 33 67 85 30 70 86 85 15 96 48 15

[0168] This method was used to detect impurities in samples 1-3.

[0169] Table 11: Effect of solvent composition on stability

[0170]

[0171]

[0172] As shown in Table 11, UB and VT are more stable in solutions containing SBECD.

[0173] Sodium sulfobutyl ether β-cyclodextrin significantly improved the solubility of umeclidinium bromide and vilanterol, with a faster dissolution rate than Tween 80 at 0.20 mg / ml.

[0174] Comparing the data from day 7 and day 14, it can be seen that sodium sulfobutyl ether beta-cyclodextrin significantly improved the stability of the UB-VT solution. There was no significant increase in the impurity content after 7 days at 40°C or 60°C, and there was basically no change from day 0. The UB-VT solution with Tween-80 had more impurities, and although 5% Tween-80 was better than 0.2 mg / ml, it was not as effective as SBECD at the same concentration.

[0175] Sodium sulfobutyl ether β-cyclodextrin is superior to Tween-80 in improving solubility and stability.

[0176] Embodiment 11

[0177] pH Stability:

[0178] The pH value of the solution has a significant effect on the solubility and stability of vilanterol triphenylacetate and umeclidinium bromide. We compared the effects of different pH values ​​on the stability.

[0179] We designed several different formulations and examined the effect of different pH values ​​on formulation stability. The formulations and stability results are shown in the table below.

[0180] Table 12: Composition of UB and VT at different pH values

[0181]

[0182] Preparation method:

[0183] SBECD was dissolved in 40 ml of purified water according to the amounts provided in Table 12. UB and VT were added to the solution according to the amounts provided in Table 12 and the resulting mixture was sonicated until the components were completely dissolved. The solution was adjusted to the target pH value shown in Table 12 with hydrochloric acid. Finally, purified water was added to provide a final weight of 50 g.

[0184] Table 13: Stability at different pH values

[0185]

[0186]

[0187] When the solution was prepared at low pH, there was no significant change in the solution, indicating that SBECD had a protective and stabilizing effect on vilanterol, preventing the triphenylacetic acid group from being replaced by hydrochloric acid.

[0188] By comparing the impurity data on day 0 and day 7, it can be seen that pH 4.0 exhibits the best stability. When the pH is not adjusted, the UB-VT content decreases significantly over time and the impurities increase significantly. Therefore, it is necessary to adjust the pH to ensure good stability.

[0189] The content of active agent showed some increase on day 14, which may be a natural error of the analysis. In terms of impurities at day 14, pH 4.0 and pH 5.0 outperformed the other pH values, with pH 5.0 outperforming pH 4.0.

[0190] Example 12

[0191] Stability comparison experiment

[0192] Table 14: Composition of Samples 9-11

[0193] Element Sample 9 Sample 10 Sample 11 UB 5.57mg 5.57mg 5.57mg VT 3mg 3mg 3mg SBECD 2.0g 2.0g 2.0g NaCl 750mg 750mg 750mg HCl Add to pH 4.00 Add to pH 4.50 Add to pH 5.00 Purified water Add to 101.1g Add to 101.1g Add to 101.1g

[0194] Preparation method:

[0195] SBECD and NaCl were dissolved in 90 ml of purified water according to Table 14. UB and VT were added to the solution and the resulting mixture was sonicated until the components were completely dissolved. The solution was adjusted to the target pH value shown in Table 14 with hydrochloric acid. Finally, purified water was added to provide a final weight of 101.1 g.

[0196] Table 15: Stability results of samples 9-11 (conditions: 40°C ± 2°C / 75% ± 5% RH)

[0197]

[0198] Table 16: Stability results of sample 9 (conditions: 40°C ± 2°C / 75% ± 5% RH)

[0199]

[0200] Table 17: Composition of Sample 12

[0201] Element Sample 12 UB 21mg VT 11mg 50% BAC 20mg Twain-80 40mg 95% ethanol 20g EDTA 11mg Purified water Add to 100ml

[0202] Preparation method:

[0203] The components of sample 12 are listed in Table 17. According to Table 17, 50% benzalkonium chloride and Tween 80 are dissolved in 20g95% ethanol respectively (add in batches according to about 6 milliliters, about 6 milliliters, about 8 milliliters). Then the resulting solution is transferred to a 100ml volumetric flask. According to the amount in Table 17, vilanterol triphenylacetate and umeclidinium bromide are added to the solution and the resulting mixture is subjected to ultrasonic treatment until the component is completely dissolved. According to the amount in Table 17, disodium ethylenediaminetetraacetic acid dihydrate is added to the solution and the resulting mixture is subjected to ultrasonic treatment until the component is completely dissolved. Finally, the flask is constant to volume with purified water.

[0204] Table 18: Stability results of sample 12

[0205]

[0206] Table 19: Stability results of sample 12 (condition: 25°C)

[0207] Impurities 1Month 2Months 3Months Total impurities of UB and VT (%) 3.17 3.51 4.49

[0208] Table 20: Stability results of sample 12 (condition: 40°C)

[0209] Impurities 1Month 2Months 3Months Total impurities of UB and VT (%) 6.83 11.33 15.95

[0210] Comparing the content and impurity data of samples 9-11 with sample 12, the total impurities of sample 12 containing alcohol and Tween-80 increased over time when stored at 25°C. The total impurities at 25°C after 3 months were 4.49%. After adding sulfobutyl ether b-cyclodextrin to samples 9-11, the total amount of impurities in the solution was less, and the total amount of impurities was about 3% after 3 months at 25°C, which was lower than the total amount of impurities in sample 12. The total amount of impurities in sample 12 stored at 40°C for 3 months was 15.95%, while the total impurity content of samples 9-11 was about 3%, which was a smaller increase compared to sample 12 stored at 25°C for 3 months. When the samples contained sulfobutyl ether b-cyclodextrin, the total impurities were significantly reduced.

[0211] Example 13

[0212] We compared the aerosols generated from homemade samples and from Oulaxin powder using the Next Generation Drug Impactor (NGI). The results are as follows:

[0213] The composition of the homemade sample (Sample 13) is shown in Table 21.

[0214] Table 21: Composition of Sample 13

[0215] Element Sample 13 UB 3.71mg VT 2mg SBECD 2.5g NaCl 300mg HCl Add to target pH 4.0 Purified water Add to 50g

[0216] Preparation of Sample 13:

[0217] Weigh the specified amount of NaCl into a beaker, add about 20g of pure water, and stir with a glass rod until completely dissolved. Add 2.5g of SBECD to the beaker, then add about 47g of pure water, and stir with a glass rod to dissolve. Adjust the pH to 4.03 with hydrochloric acid. Add UB and VT, place the resulting mixture on a magnetic stirrer, and continue stirring until the components are completely dissolved. After UB and VT are completely dissolved, make the solution 50.0g with pure water.

[0218] The particle size distribution was determined using NGI (experimental flow rate 15 L / min, experimental atomization device PARI e-Flow).

[0219] Aerodynamic particle size distribution:

[0220] The aerodynamic particle size distribution was determined using a Next Generation Drug Impactor (NGI). A soft mist inhaler was placed close to the NGI inlet until no aerosol was visible. The NGI flow rate was set to 30 L / min and operated at ambient temperature and 90% relative humidity (RH).

[0221] The solution of sample 13 was discharged into the NGI. Depending on the particle size of the fraction, the dosed fractions were deposited at different stages of the NGI. Each fraction was washed off the stage and analyzed using HPLC.

[0222] The results are shown in Table 22.

[0223] Table 22: Aerodynamic Particle Size Distribution of Sample 13

[0224]

[0225] MOC is microporous collector.

[0226] ISM is the impactor size mass.

[0227] FPF is the fine particle fraction.

[0228] MMAD is the mass median aerodynamic diameter.

[0229] GSD is the geometric standard deviation.

[0230] Class F is the filter, which is a DDU tube connected to the end of the NGI.

[0231] Comparative experiment:

[0232] The NGI was used to characterize an aerosol formulation of umeclidinium and vilanterol triphenylacetate inhalation powder from the original ANQRO ELLIPTA, purchased from Glaxo Operations UK Ltd. Each delivered dose contained 40 micrograms VT and 74.2 micrograms UB. The NGI results are provided in Table 23. The NGI test was performed (experimental flow rate 30 L / min, experimental nebulization apparatus was the apparatus provided with the ANORO ELLIPTA formulation).

[0233] Table 23: Aerodynamic particle size distribution of ANORO ELLIPTA

[0234]

[0235] SI is stage 1

[0236] Comparing the NGI parameters of the ANORO ELLIPTA formulation and the homemade formulation, it can be seen that the effective lung deposition of the homemade formulation is much higher than that of the ANORO ELLIPTA formulation, indicating that the bioavailability of the homemade formulation sprayed with the E-flow device is higher.

[0237] The results of the NGI analysis showed that most of the active ingredient was distributed in S3 to S5, indicating that the formulation of the present invention provided good lung deposition.

[0238] Since the ISM of the homemade preparation is much higher than that of the original study, in order to be consistent with the original study, it is considered that the effective doses of vilanterol triphenylacetate and umeclidinium bromide can be reduced. In one embodiment, the daily dose of UB is about 55.7 micrograms and the daily dose of VT is about 30 micrograms.

Claims

1. A liquid pharmaceutical preparation without a propellant, comprising: (a) Umeclidinium bromide and vilanterol triphenylacetate; (b) water; (c) sulfobutyl ether β-cyclodextrin, wherein the pH of the formulation ranges from 4.0 to 5.0; The umeclidinium bromide is present in an amount ranging from 2 mg / 100 ml to 350 mg / 100 ml; The vilanterol triphenylacetate is present in an amount of 1 mg / 100 ml to 200 mg / 100 ml; The sulfobutyl ether β-cyclodextrin is present in an amount of 1 g / 100 ml to 40 g / 100 ml.

2. The pharmaceutical preparation according to claim 1, further comprising a preservative, wherein the preservative is selected from one or more of benzalkonium chloride, benzoic acid and sodium benzoate.

3. The pharmaceutical formulation of claim 2, wherein the preservative is present in an amount ranging from 2 mg / 100 ml to 300 mg / 100 ml.

4. The pharmaceutical preparation of claim 1, further comprising a stabilizer selected from edetic acid, edetate disodium, citric acid and a combination thereof.

5. The pharmaceutical formulation of claim 4, wherein the stabilizer is present in an amount of 1 mg / 100 ml to 500 mg / 100 ml.

6. Use of a pharmaceutical formulation as claimed in any one of claims 1 to 5 in the preparation of a medicament for treating asthma or COPD, comprising forming an inhalable aerosol by atomising the pharmaceutical formulation by forcing a defined amount of the pharmaceutical formulation through a nozzle using pressure.

7. The method of claim 6, wherein the defined amount of the pharmaceutical preparation is less than 70 microliters.

8. The use according to claim 6, wherein the mass median aerodynamic diameter (MMAD) of vilanterol triphenylacetate and umeclidinium bromide is less than 10 μm.

9. The use according to claim 6, wherein The geometric standard deviations (GSD) of vilanterol triphenylacetate and umeclidinium bromide were less than 5%.

10. The use according to claim 6, wherein the particle size distribution of the aerosol has a Dv10 of less than 4 μm, a Dv50 of less than 7 μm and a Dv90 of less than 12 μm.

11. The use according to claim 6, wherein The daily dose of umeclidinium is 15 micrograms to 110 micrograms, while the daily dose of vilanterol triphenylacetate is 9 micrograms to 60 micrograms.

12. A liquid pharmaceutical preparation without a propellant, comprising: Aqueous solution: (a) umeclidinium bromide in an amount of 2 mg / 101 g to 350 mg / 101 g of the preparation; (b) vilanterol triphenylacetate, in an amount of 1 mg / 101 g to 200 mg / 101 g of the preparation; (c) sulfobutyl ether β-cyclodextrin SBECD, in an amount of 1 g / 101 g to 40 g / 101 g of the preparation; (d) sodium chloride, in an amount of 100 mg / 101 g to 900 mg / 101 g of the preparation; wherein the pH value of the solution is 4.0 to 5.0.